Lunai Bioworks discovers 3 Parkinson's subtypes, targets for $13B market. Exciting progress in precision therapeutics.
Today, in Sacramento, California, Lunai Bioworks (NASDAQ: LNAI), a biotechnology company utilizing AI to develop precision therapeutics, revealed the discovery of three significant subtypes of Parkinson's disease. They have also prioritized drug targets that show promise for treatment.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments